Association between circulating prolactin levels and psoriasis and its correlation with disease severity: a meta-analysis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Studies that have compared circulating prolactin (PRL) levels in patients with psoriasis and healthy controls (HCs) and determined the relation between PRL levels and psoriasis severity have shown mixed results. Aim: To evaluate the association between circulating PRL levels and psoriasis, and between serum/plasma PRL levels and psoriasis severity. Methods: We performed a meta-analysis comparing serum/plasma PRL levels in patients with psoriasis with those of HCs, and examined the correlation coefficients for circulating PRL levels and psoriasis severity based on Psoriasis Area and Severity Index (PASI). Results: In total, 12 studies assessing 446 patients with psoriasis and 401 HCs were included. PRL levels were significantly higher in the psoriasis group than in the HC group [standardized mean difference (SMD) 0.54; 95% CI = 0.18–090; P < 0.01). Stratification by age and sex revealed a significantly higher PRL level in the psoriasis group (SMD = 0.53; 95% CI = 0.15–0.91; P < 0.01). Subgroup analysis by sample size showed a significantly higher PRL level with larger sample sizes (n ≥ 80) (SMD = 0.51, 95% CI = 0.07–0.95, P = 0.02), but not with smaller sample sizes (n < 80) in the psoriasis group. Stratification by sample type revealed a significantly higher level of PRL in the sera, but not plasma of the psoriasis group. Meta-analysis of the correlation coefficients showed a positive, although not statistically significant, correlation between circulating PRL levels and PASI (correlation coefficient = 0.48, 95% CI = −0.05 to 0.80, P = 0.08). Conclusion: Circulating PRL levels are higher in patients with psoriasis, and PRL levels may correlate with psoriasis severity.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalClinical and Experimental Dermatology
Volume43
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Psoriasis
Prolactin
Meta-Analysis
Sample Size
Serum

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{5056c7ec41f34af082d98e2c749565a6,
title = "Association between circulating prolactin levels and psoriasis and its correlation with disease severity: a meta-analysis",
abstract = "Background: Studies that have compared circulating prolactin (PRL) levels in patients with psoriasis and healthy controls (HCs) and determined the relation between PRL levels and psoriasis severity have shown mixed results. Aim: To evaluate the association between circulating PRL levels and psoriasis, and between serum/plasma PRL levels and psoriasis severity. Methods: We performed a meta-analysis comparing serum/plasma PRL levels in patients with psoriasis with those of HCs, and examined the correlation coefficients for circulating PRL levels and psoriasis severity based on Psoriasis Area and Severity Index (PASI). Results: In total, 12 studies assessing 446 patients with psoriasis and 401 HCs were included. PRL levels were significantly higher in the psoriasis group than in the HC group [standardized mean difference (SMD) 0.54; 95{\%} CI = 0.18–090; P < 0.01). Stratification by age and sex revealed a significantly higher PRL level in the psoriasis group (SMD = 0.53; 95{\%} CI = 0.15–0.91; P < 0.01). Subgroup analysis by sample size showed a significantly higher PRL level with larger sample sizes (n ≥ 80) (SMD = 0.51, 95{\%} CI = 0.07–0.95, P = 0.02), but not with smaller sample sizes (n < 80) in the psoriasis group. Stratification by sample type revealed a significantly higher level of PRL in the sera, but not plasma of the psoriasis group. Meta-analysis of the correlation coefficients showed a positive, although not statistically significant, correlation between circulating PRL levels and PASI (correlation coefficient = 0.48, 95{\%} CI = −0.05 to 0.80, P = 0.08). Conclusion: Circulating PRL levels are higher in patients with psoriasis, and PRL levels may correlate with psoriasis severity.",
author = "Lee, {Young Ho} and Song, {Gwan Gyu}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ced.13228",
language = "English",
volume = "43",
pages = "27--35",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Association between circulating prolactin levels and psoriasis and its correlation with disease severity

T2 - a meta-analysis

AU - Lee, Young Ho

AU - Song, Gwan Gyu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Studies that have compared circulating prolactin (PRL) levels in patients with psoriasis and healthy controls (HCs) and determined the relation between PRL levels and psoriasis severity have shown mixed results. Aim: To evaluate the association between circulating PRL levels and psoriasis, and between serum/plasma PRL levels and psoriasis severity. Methods: We performed a meta-analysis comparing serum/plasma PRL levels in patients with psoriasis with those of HCs, and examined the correlation coefficients for circulating PRL levels and psoriasis severity based on Psoriasis Area and Severity Index (PASI). Results: In total, 12 studies assessing 446 patients with psoriasis and 401 HCs were included. PRL levels were significantly higher in the psoriasis group than in the HC group [standardized mean difference (SMD) 0.54; 95% CI = 0.18–090; P < 0.01). Stratification by age and sex revealed a significantly higher PRL level in the psoriasis group (SMD = 0.53; 95% CI = 0.15–0.91; P < 0.01). Subgroup analysis by sample size showed a significantly higher PRL level with larger sample sizes (n ≥ 80) (SMD = 0.51, 95% CI = 0.07–0.95, P = 0.02), but not with smaller sample sizes (n < 80) in the psoriasis group. Stratification by sample type revealed a significantly higher level of PRL in the sera, but not plasma of the psoriasis group. Meta-analysis of the correlation coefficients showed a positive, although not statistically significant, correlation between circulating PRL levels and PASI (correlation coefficient = 0.48, 95% CI = −0.05 to 0.80, P = 0.08). Conclusion: Circulating PRL levels are higher in patients with psoriasis, and PRL levels may correlate with psoriasis severity.

AB - Background: Studies that have compared circulating prolactin (PRL) levels in patients with psoriasis and healthy controls (HCs) and determined the relation between PRL levels and psoriasis severity have shown mixed results. Aim: To evaluate the association between circulating PRL levels and psoriasis, and between serum/plasma PRL levels and psoriasis severity. Methods: We performed a meta-analysis comparing serum/plasma PRL levels in patients with psoriasis with those of HCs, and examined the correlation coefficients for circulating PRL levels and psoriasis severity based on Psoriasis Area and Severity Index (PASI). Results: In total, 12 studies assessing 446 patients with psoriasis and 401 HCs were included. PRL levels were significantly higher in the psoriasis group than in the HC group [standardized mean difference (SMD) 0.54; 95% CI = 0.18–090; P < 0.01). Stratification by age and sex revealed a significantly higher PRL level in the psoriasis group (SMD = 0.53; 95% CI = 0.15–0.91; P < 0.01). Subgroup analysis by sample size showed a significantly higher PRL level with larger sample sizes (n ≥ 80) (SMD = 0.51, 95% CI = 0.07–0.95, P = 0.02), but not with smaller sample sizes (n < 80) in the psoriasis group. Stratification by sample type revealed a significantly higher level of PRL in the sera, but not plasma of the psoriasis group. Meta-analysis of the correlation coefficients showed a positive, although not statistically significant, correlation between circulating PRL levels and PASI (correlation coefficient = 0.48, 95% CI = −0.05 to 0.80, P = 0.08). Conclusion: Circulating PRL levels are higher in patients with psoriasis, and PRL levels may correlate with psoriasis severity.

UR - http://www.scopus.com/inward/record.url?scp=85030124357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030124357&partnerID=8YFLogxK

U2 - 10.1111/ced.13228

DO - 10.1111/ced.13228

M3 - Article

C2 - 28940303

AN - SCOPUS:85030124357

VL - 43

SP - 27

EP - 35

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 1

ER -